Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 23, 2012

View Archived Issues

Gilead Sciences describes work on new dual beta2-adrenoceptor agonist/PDE4 inhibitors

Bristol-Myers Squibb reports discovery and first clinical data for new 11-beta-HSD1 inhibitor

FluCide drug candidates show oral efficacy in animal model

HTS hit-to-lead discovery program yields new GSK-3 beta inhibitors

Takeda presents new potent IAP inhibitors with promising oncolytic activity

ActoGeniX reports on phase I AG-013 trial

AstraZeneca updates progress of second quarter 2012

Prana provides update on Alzheimer's and Huntington's disease programs

Allergan and Molecular Partners expand collaboration

Collaboration yields novel potential analgesics

New agents for use in stem cell transplants disclosed

New TRPM8 channel antagonists disclosed by Dompe Farmaceutici

Bristol-Myers Squibb presents new beta-amyloid production inhibitors

Novel potential cognition-enhancing drugs designed

U.S. university develops new anticancer products

Novel candidate anticancer drugs synthesized in U.S.

Industry spotlight: Orphan drug R&D is a viable biopharma strategy

Kyowa Hakko Kirin launches pivotal mogamulizumab trial

AspenBio Pharma raises funds to develop AppyScore

Phase I trial of new TB vaccine candidate commences

Folate-rapamycin conjugate shows promise to treat PKD

EMA accepts MAA for Heplisav

Pluristem set to kick off phase II trial in intermittent claudication

Gevokizumab obtains orphan drug status for new indication

OXiGENE and Azanta expand Zybrestat agreement

U.K. authorities approve flutiform

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...